Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency episodes, and quality of life indicators compared to placebo, 12 weeks post-administrati...
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product URO-902 (hMaxi-K), showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo.
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $75.0 million
Deal Type : Licensing Agreement
Details : Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
Product Name : Obgemsa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 07, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $75.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB).
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder and urge urinary incontinence will be featured in a late-breaker presentation during plenary session.
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Therapeutics and Clinical Risk Management paper points out that in international phase 3 EMPOWUR trial, treatment with GEMTESA was associated with significant improvements compared with placebo.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data on GEMTESA® (vibegron) 75 mg
Details : New data from dedicated ambulatory blood pressure study of patients with overactive bladder (OAB) showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rat...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The commercial launch of GEMTESA, a beta-3 (β3) adrenergic receptor agonist, was announced in April 2021. EMTESA reduces the bothersome symptoms of OAB by relaxing the detrusor bladder muscle so that the bladder can hold more urine.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable